Clinical Trials Logo
  1. Home
  2. Pulmonary Fibrosis
  3. NCT00515567
  4. Details
NCT00515567 Clinical Trial

Explanted Lung Tissues With Pulmonary Fibrosis

Pulmonary Fibrosis Clinical Trial

Official title:
Utilization of Explanted Lungs for Isolation of Tissue Samples and Primary Cell Lines to Study Pulmonary Fibrosis

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT00515567
Other study ID # 14514A
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 2006
Est. completion date December 2024

Study information
Verified date November 2023
Source University of Chicago
Contact Nickolai Dulin, MD
Email ndulin@bsd.uchicago.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this study is to use the tissues from the explanted lungs in order to better study the cause of pulmonary fibrosis at a cellular level.

Description:

Pulmonary Fibrosis involves scarring of the lung. Gradually, the air sacs of the lungs become replaced by fibrotic tissue. The most current thinking is that the fibrotic process is a reaction to tiny injury to the lung. When the scar forms, the tissue becomes thicker causing a permanent loss of the tissue's ability to carry oxygen into the bloodstream. We need to obtain lung tissue from patients without pulmonary fibrosis and compare it to lung tissue from patients with pulmonary fibrosis.

Recruitment information / eligibility
Status Recruiting
Enrollment 90
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - all patients awaiting lung transplant Exclusion Criteria: - all who will not give consent

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United States The University of Chicago Chicago Illinois

Sponsors (1)
Lead Sponsor Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary assess fibroblasts and cytokines associated with pulmonary fibrosis 12/2013
See also
  Status Clinical Trial Phase
Recruiting NCT04638517 - The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis Phase 2
Recruiting NCT05299333 - Comparison of Pulmonary Telerehabilitation and Physical Activity Recommendations in Patients With Post Covid Fibrosis N/A
Terminated NCT04119115 - Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT01417156 - Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174) Phase 2
Terminated NCT00981747 - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Phase 2/Phase 3
Completed NCT00001596 - Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome Phase 2
Completed NCT00052052 - An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Completed NCT01442779 - Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Recruiting NCT00001532 - Role of Genetic Factors in the Development of Lung Disease
Recruiting NCT04767074 - A Non-pharmacological Cough Control Therapy N/A
Recruiting NCT04864990 - Dyspnea and Idiopathic Pulmonary Fibrosis
Completed NCT01961362 - Supplemental Oxygen in Pulmonary Fibrosis
Completed NCT01271842 - Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study N/A
Completed NCT00650091 - Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Phase 3
Active, not recruiting NCT00258544 - Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
Enrolling by invitation NCT04930289 - Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
Completed NCT02055222 - Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Enrolling by invitation NCT06327360 - Illness Expectations in Pulmonary Fibrosis